Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

Financial health

Theravance Biopharma, Inc. financial health

Start with the overall verdict and the rule-based risk checks for TBPH, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Resilient

Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.

Cash and investments cover debt Healthy short-term liquidity Moderate leverage

Cash & Investments

$395.50M

Debt Cushion

$322.20M

Current Ratio

13.1x

Interest Coverage

Not available

Risk checks

1 of 11 checks flagged

  • Interest coverage

    0.0×

    Passes when: Operating income is at least 1.5 times interest expense.

  • Positive equity

    Positive

    Passes when: Shareholders’ equity is above zero.

  • Short-term liquidity

    13.1×

    Passes when: Current assets are at least 1 times current liabilities.

  • Near-term debt coverage

    36.7×

    Passes when: Cash and short-term investments cover debt due within 12 months.

  • Manageable net debt

    Net cash

    Passes when: Net debt is below 3 times EBITDA.

  • Debt repayment from cash flow

    0.3 yr

    Passes when: Free cash flow could repay all debt within 5 years.

  • Debt growth versus revenue growth

    13.1% vs. 27.9%

    Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.

  • Tangible equity base

    0.0%

    Passes when: Goodwill and intangibles are below 50% of equity.

  • Altman Z-score trend

    -2.09 → 1.58

    Passes when: The Z-score is stable or rising, or stays above 2.99.

  • Stock-based compensation

    6.7%

    Passes when: Stock-based compensation is no more than 20% of operating cash flow.

  • Share dilution

    -3.7% per year

    Passes when: Diluted share count grows no more than 2% per year.

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

No financial scores available.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$288.10M

Q1 2026

3Y +0.7%1Y +71.7%

Quick Ratio

13.1x

Q1 2026

Current Ratio

13.1x

Q1 2026

Cash Ratio

9.1x

Q1 2026

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Working capital (Q1 2026)

$385.86M

Current assets − current liabilities

Days sales outstanding

324 d

-64 days vs. prior year

Days inventory outstanding

0 d

+0 days vs. prior year

Days payables outstanding

170 d

+148 days vs. prior year

Cash conversion cycle

155 d

-212 days vs. prior year

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$73.30M

Q1 2026

3Y +16.4%1Y -2.9%

Debt/Equity

0.3x

Q1 2026

Debt/Assets

0.2x

Q1 2026

Interest Coverage

—

Q1 2026

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Net debt

Net cash: $321.37M

Total debt − cash − short-term investments

Net debt / EBITDA

Net cash

Above 3× is elevated

Free cash flow / debt

366.6%

Share of debt one year of FCF could repay

Years to repay debt

0.3 yr

Total debt ÷ free cash flow

Operating cash flow / current liabilities

8.5×

Above 1× funds a year of obligations

Interest coverage

0.0×

Operating income ÷ interest expense

Debt maturity

Cash and short-term investments cover short-term debt 36.7×.

Due within 12 months$10.75MDue later$32.8M

Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$836,000.00

Q1 2026

1Y -94.2%

Assets

$472.31M

Q1 2026

3Y +3.5%1Y -2.7%

Liabilities

$181.72M

Q1 2026

3Y -3.3%1Y -3.8%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q1 2026).

Claims on $472.31M in assets

  • Payables0.2%
  • Short-term debt2.3%
  • Long-term debt6.9%
  • Other liabilities29.0%
  • Equity61.5%

Goodwill + intangibles

$0

0.0% of total assets

Share of equity

0.0%

Above 50% leaves little tangible backing

Tangible equity

$290.59M

Equity left after writing off goodwill and intangibles

Deferred revenue

$0

Customer prepayments: a liability settled by delivering service, not cash

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

-3.7%

Compound annual rate from FY 2020 to FY 2025

Stock-based compensation

$18.1M

6.7% of operating cash flow

Dividends paid

None

TTM to Q1 2026

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

$8.98M

TTM to Q1 2026

Weighted diluted shares outstanding

Competitor health

How does Theravance Biopharma, Inc. compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

Vir Biotechnology, Inc.

VIR:NASDAQ

$1.80B0.240.190.11—5.545.542.52

ArriVent BioPharma, Inc.

AVBP:NASDAQ

$1.33B0.000.000.27—12.8312.831.76

Tyra Biosciences, Inc.

TYRA:NASDAQ

$1.30B0.020.020.60—14.6714.674.28

Replimune Group, Inc.

REPL:NASDAQ

$1.04B0.180.140.14—7.957.951.78

Monte Rosa Therapeutics, Inc.

GLUE:NASDAQ

$994.32M0.170.092.89—6.126.122.02

Geron Corporation

GERN:NASDAQ

$808.32M1.110.44Net cash—4.664.660.71

Valneva SE

VALN:NASDAQ

$582.22M1.950.52Net cash—1.852.381.17

LENZ Therapeutics, Inc.

LENZ:NASDAQ

$122.75M0.000.000.30—13.8013.801.19

Questions

Financial health questions

Common questions about TBPH's balance sheet, answered from the reported figures.

Is TBPH's balance sheet healthy?

Theravance Biopharma, Inc. (TBPH) has a current ratio of 13.14, a quick read on short-term liquidity.

How leveraged is TBPH?

Debt to equity is 0.25, which helps judge how much financing risk sits on the balance sheet.